Clinical Trial Update: Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating neratinib tablets for advanced non-small cell lung cancer with rare EGFR mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• neratinib (neratinib)

Snippet

Sponsor: Convalife (Shanghai) Co., Ltd. | Conditions: NSCLC | Phase 2 | Status: UNKNOWN